Granules India
Granules India Limited, headquartered in Hyderabad, India, is a prominent player in the pharmaceutical industry, specialising in the manufacture of active pharmaceutical ingredients (APIs), pharmaceutical formulations, and over-the-counter (OTC) products. Founded in 1984, the company has achieved significant milestones, including the establishment of state-of-the-art manufacturing facilities across India and a strong global presence in markets such as the United States and Europe. Granules India is renowned for its commitment to quality and innovation, offering a diverse range of core products that include paracetamol, ibuprofen, and metformin. The company’s unique approach to integrated manufacturing sets it apart, enabling cost-effective production while maintaining high standards. With a robust market position, Granules India has garnered recognition for its sustainable practices and has received multiple certifications from regulatory bodies, solidifying its reputation as a trusted partner in the pharmaceutical sector.
DitchCarbon Score
How does Granules India's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Granules India's score of 51 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Granules India's reported carbon emissions
In 2023, Granules India reported total greenhouse gas emissions of approximately 109,950,000 kg CO2e. This includes Scope 1 emissions of about 15,975,000 kg CO2e, Scope 2 emissions of approximately 22,897,000 kg CO2e, and significant Scope 3 emissions totalling around 353,681,000 kg CO2e. The combined Scope 1 and 2 emissions amounted to about 112,571,000 kg CO2e. Granules India has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its entire value chain by FY2050. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 42% by FY2030, using FY2023 as the baseline year. Additionally, Granules India plans to increase its sourcing of renewable electricity from 0% in FY2023 to 100% by FY2030. The company also aims to reduce absolute Scope 3 emissions by 42% by FY2030. For long-term goals, Granules India is committed to a 90% reduction in both Scope 1 and 2 emissions and Scope 3 emissions by FY2050, again using FY2023 as the baseline. These targets align with the Science Based Targets initiative (SBTi) and reflect the company's commitment to addressing climate change within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 14,652,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 16,399,000 | 00,000,000 | 0,000,000 |
| Scope 3 | 325,494,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Granules India is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
